Adenosine A(2A) receptor antagonist istradefylline reduces daily OFF time in Parkinson%26apos;s disease

作者：Mizuno Yoshikuni^*; Kondo Tomoyoshi

来源：Movement Disorders, 2013, 28(8): 1138-1141.

DOI：10.1002/mds.25418

• Parkinson%26apos
• s disease
• istradefylline
• levodopa
• motor complications
• wearing-off

Background: We evaluated the efficacy and safety of istradefylline, a selective adenosine A(2A) receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson%26apos;s disease patients with motor complications in Japan. %26lt;br%26gt;Methods: A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated. %26lt;br%26gt;Results: The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P=.003) and istradefylline 40 mg/day (-0.96 hours, P=.003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%). %26lt;br%26gt;Conclusions: Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.

• 出版日期2013-7